Authors: Fatima S, Zaidi SS, Alsharidah AS, Alijaser FS, Banu N. PMID: 33344529 PMCID: PMC7744567 DOI: 10.3389/fvets.2020.585789 Abstract SARS-CoV-2, an epidemic, causes severe stress in both human and animals and may induce oxidative stress (OS) and increases susceptibility to infection. Domestic animals are found infected by their COVID-2 suffering owners. Chronic immobilization stress (CIS), a [...]

Authors: Samuel RM, Majd H, Richter MN, Ghazizadeh Z, Navickas A, Ramirez JT PMID: 33232663 PMCID: PMC7670929 DOI: 10.1016/j.stem.2020.11.009 Abstract SARS-CoV-2 infection has led to a global health crisis, and yet our understanding of the disease and potential treatment options remains limited. The infection occurs through binding of the virus with angiotensin converting enzyme 2 [...]

Authors: Ashraf S, Ashraf S, Ashraf M, Imran MA, Kalsoom L, Siddiqui UN et al. PMID: 36420866 DOI: 10.1002/ptr.7640 Abstract Until now, no specific and effective treatment exists for coronavirus disease 2019 (COVID-19). Since honey and Nigella sativa (HNS) have established antiviral, antibacterial, antiinflammatory, antioxidant, and immunomodulatory properties, we tested their efficacy for this disease [...]

Authors: Murai IH, Fernandes AL, Sales LP, Pinto AJ, Goessler KF. doi: https://doi.org/10.1101/2020.11.16.20232397 Abstract Importance Patients with COVID-19 may exhibit 25-hydroxyvitamin D deficiency, but the beneficial effects of vitamin D3 supplementation in this disease remain to be proven by randomized controlled trials. Objective To investigate the efficacy and safety of vitamin D3 supplementation in patients [...]

Authors: Arslan B, Ergun NU, Topuz S, Semerci SY, Suner N. DOI: 10.2139/ssrn.3682517 Abstract Background: While waiting for vaccine, hygiene measures, social distance and personal protective equipment are the only basic protection against Novel Coronavirus. However, these are not sufficient to protect healthcare workers.This study aimed to evaluate if quercetin and vitamin C could be [...]

Authors: McCoy J, Cadegiani FA, Wambler CG, Herrera S, Goren A PMID: 33135263 DOI: 10.1111/jdv.17021 Abstract We have previously reported that men with androgenetic alopecia (AGA) are more likely to present with severe COVID-19 symptoms, potentially implicating androgen sensitivity as a risk factor for COVID-19.1-3 As such, we hypothesized that 5-alpha-reductase inhibitors (5ARi) may reduce [...]

Authors: Risch HA PMID: 32458969 PMCID: PMC7546206 DOI: 10.1093/aje/kwaa093 Abstract More than 1.6 million Americans have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and more than 10 times that number carry antibodies to it. High-risk patients with progressing symptomatic disease currently have only hospitalization treatment, with its high mortality, available to them. [...]

Authors: Shi Z, Puyo CA PMID: 33177829 PMCID: PMC7649937 DOI: 10.2147/TCRM.S273700 Abstract The novel coronavirus disease (COVID-19) is caused by a virus (SARS-Cov-2) and is known for inducing multisystem organ dysfunction associated with significant morbidity and mortality. Current therapeutic strategies for COVID-19 have failed to effectively reduce mortality rate, especially for elderly patients. A newly [...]

Authors:Frank S, Brown SM, Capriotti JA, Westover JB, Pelletier JS. PMID: PMC7499242 DOI: 10.1001/jamaoto.2020.3053 Abstract Importance: Research is needed to demonstrate the efficacy of nasal povidone-iodine (PVP-I) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Objective: To evaluate the in vitro efficacy of PVP-I nasal antiseptic for the inactivation of SARS-CoV-2 at clinically significant contact [...]

COVID-19 patients suffer from the lack of curative therapy. Hence, there is an urgent need to try repurposed old drugs on COVID-19. Methods Randomized controlled study on 70 COVID-19 patients (48 mild-moderate, 11 severe, and 11 critical patients) treated with 200ug/kg PO of Ivermectin per day for 2-3 days along with 100mg PO doxycycline twice per day for 5-10 days plus standard therapy; the second arm is 70 COVID-19 patients (48 mild-moderate and 22 severe and zero critical patients) on standard therapy. The time to recovery, the progression of the disease, and the mortality rate were the outcome-assessing parameters.